

Version: 2.0 Page 1 of 11 Revision date: 01-Apr-2015

# **IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING**

**Product Identifier** 

Material Name: Conjugated Estrogens Vaginal Cream (US)

**PREMARIN Trade Name: Chemical Family:** Steroid

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for hormone replacement therapy

Details of the Supplier of the Safety Data Sheet

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017

1-800-879-3477

**Emergency telephone number:** CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd Ramsgate Road Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161

**Emergency telephone number:** 

International CHEMTREC (24 hours): +1-703-527-3887

### HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

Not classified as hazardous GHS - Classification

**EU Classification:** 

EU Indication of danger: Not classified

**Label Elements** 

Signal Word: Not required

**Hazard Statements:** Non-hazardous in accordance with international standards for workplace safety.

Other Hazards No data available

**Australian Hazard Classification** 

(NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

This document has been prepared in accordance with standards for workplace safety, which Note:

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

### **Hazardous**

PZ01446

Page 2 of 11

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015 Version: 2.0

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Cetyl alcohol	36653-82-4	253-149-0	Not Listed	Not Listed	*
Sodium lauryl sulfate	151-21-3	205-788-1	Not Listed	Not Listed	*
Glyceryl monostearate	31566-31-1	250-705-4	Not Listed	Not Listed	*
Benzyl Alcohol	100-51-6	202-859-9	Xn; R20/22	Acute Tox.4 (H302) Acute Tox.4 (H332)	*
Glycerin, USP	56-81-5	200-289-5	Not Listed	Not Listed	*
Conjugated estrogens	12126-59-9	235-199-5	Carc.Cat.1;R45 Repr.Cat.1;R60 Repr.Cat.1;R61	Carc. 1A,H350; Repr. 1A,H360FD	0.0625

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
White wax	8006-40-4	Not Listed	Not Listed	Not Listed	*
Water, purified	7732-18-5	231-791-2	Not Listed	Not Listed	*
Methyl stearate	112-61-8	203-990-4	Not Listed	Not Listed	*
Mineral oil, white	8042-47-5	232-455-8	Not Listed	Not Listed	*
Cetyl stearate	1190-63-2	214-724-1	Not Listed	Not Listed	*
Fatty acids, C16-18, esters with propylene glycol	91031-35-5	292-936-3	Not Listed	Not Listed	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has

been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

## 4. FIRST AID MEASURES

**Description of First Aid Measures** 

**Eye Contact:** Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get

medical attention.

**Skin Contact:** Wash off immediately with soap and plenty of water If irritation occurs or persists, get medical

attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

Page 3 of 11

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015 Version: 2.0

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion** Formation of toxic gases is possible during heating or fire.

**Products:** 

Fire / Explosion Hazards: Not applicable

**Advice for Fire-Fighters** 

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

**Collecting:** area thoroughly.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report emergency

Large Spills: situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

### **Precautions for Safe Handling**

Avoid breathing mist or aerosols. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

Cetyl alcohol

Germany - TRGS 900 - TWAs 20 ppm

200 mg/m<sup>3</sup>

Sodium lauryl sulfate

Pfizer OEL TWA-8 Hr: 0.3 mg/m<sup>3</sup>

Glyceryl monostearate

ACGIH Threshold Limit Value (TWA) 10 mg/m<sup>3</sup>
Lithuania OEL - TWA 5 mg/m<sup>3</sup>

Material Name: Conjugated Estrogens Vaginal Cream (US) Page 4 of 11

Revision date: 01-Apr-2015 Version: 2.0

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Sweden OEL - TWAs 5 mg/m<sup>3</sup>

**Benzyl Alcohol** 

Bulgaria OEL - TWA 5.0 mg/m³
Czech Republic OEL - TWA 40 mg/m³
Finland OEL - TWA 10 ppm
45 mg/m³
Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 5 mg/m³
Poland OEL - TWA 240 mg/m³

Mineral oil, white

ACGIH Threshold Limit Value (TWA) 5 mg/m<sup>3</sup>

ACGIH Threshold Limit Value (STEL) 10 mg/m³ (oil mist)

Glycerin, USP

10 mg/m<sup>3</sup> **Australia TWA Belgium OEL - TWA** 10 mg/m<sup>3</sup> 10 mg/m<sup>3</sup> Czech Republic OEL - TWA Estonia OEL - TWA 10 mg/m<sup>3</sup> Finland OEL - TWA 20 mg/m<sup>3</sup> 10 mg/m<sup>3</sup> France OEL - TWA Germany (DFG) - MAK 50 mg/m<sup>3</sup> **Greece OEL - TWA** 10 mg/m<sup>3</sup> **Ireland OEL - TWAs** 10 mg/m<sup>3</sup> **OSHA - Final PELS - TWAs:** 15 ma/m<sup>3</sup> **Poland OEL - TWA** 10 mg/m<sup>3</sup> 10 mg/m<sup>3</sup> Portugal OEL - TWA Spain OEL - TWA 10 mg/m<sup>3</sup> **Switzerland OEL -TWAs** 50 mg/m<sup>3</sup>

Conjugated estrogens

Pfizer OEL TWA-8 Hr: 0.15µg/m<sup>3</sup>

**Cetyl stearate** 

ACGIH Threshold Limit Value (TWA) 10 mg/m<sup>3</sup>

**Exposure Controls** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

Refer to applicable national standards and regulations in the selection and use of personal

contamination levels below the exposure limits listed above in this section.

Personal Protective

**Equipment:** protective equipment (PPE).

Hands: Impervious, disposable gloves (double suggested) are recommended if skin contact with drug

product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is

possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

**Molecular Weight:** 

Page 5 of 11

Mixture

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015 Version: 2.0

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Cream Color: White

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture

Solvent Solubility:
Water Solubility:
PH:
No data available
No data available
No data available.
No data available.
No data available.
No data available
No data available
Partition Coefficient: (Method, pH, Endpoint, Value)

White wax
No data available
Benzyl Alcohol
No data available
Cetyl alcohol
No data available
Glycerin, USP
No data available

Sodium lauryl sulfate

No data available

Glyceryl monostearate

No data available

Conjugated estrogens

No data available

Water, purified

No data available

**Cetyl stearate** 

No data available

Mineral oil, white

No data available

Fatty acids, C16-18, esters with propylene glycol

No data available

**Decomposition Temperature (°C):** No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):No data availableFlammability (Solids):No data availableFlash Point (Liquid) (°C):No data availableUpper Explosive Limits (Liquid) (% by Vol.):No data availableLower Explosive Limits (Liquid) (% by Vol.):No data available

# 10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

**Possibility of Hazardous Reactions** 

\_\_\_\_\_

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015 Version: 2.0

## 10. STABILITY AND REACTIVITY

Oxidizing Properties: No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from strong oxidizers **Incompatible Materials:** No data available

**Hazardous Decomposition** 

Products:

### 11. TOXICOLOGICAL INFORMATION

### Information on Toxicological Effects

**General Information:** 

The information included in this section describes the potential hazards of the individual

Page 6 of 11

ingredients.

**Short Term:** May cause eve and skin irritation (based on components)

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on

> reproductive system, the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and

amenorrhea).

**Known Clinical Effects:** Clinical use of this drug has caused menstrual irregularities, lack of menstrual periods

> (amenorrhea), changes in cervical erosion and secretion, breast enlargement, breast pain, breast development in males (gynecomastia), nausea, vomiting, abdominal cramping, weight changes, fluid retention, changes in sexual desire (libido), loss of hair, mental depression,

## Acute Toxicity: (Species, Route, End Point, Dose)

### **Benzyl Alcohol**

Rat Oral LD50 1230 mg/kg Rat Para-periosteal LD50 53mg/kg Inhalation LC50 >4.178mg/L Rat

## Cetyl alcohol

Oral Rat LD50 5000 mg/kg

Rabbit LD50 > 2,600 mg/kg Dermal

LD50 3200 mg/kg Mouse Oral

### Glycerin, USP

Mouse Oral LD50 4090 mg/kg Rat Oral LD50 12.6 g/kg Rabbit Dermal LD50 > 10 g/kg

Inhalation LC50 1hr Rat  $> 570 \text{ mg/m}^3$ 

Dermal LD 50 > 21.9 g/kg Rat

# Sodium lauryl sulfate

Oral LD50 1288 mg/kg

# Glyceryl monostearate

Mouse IP LD50 200 mg/kg

#### Conjugated estrogens

LD50 325 mg/kg Rat IP

Page 7 of 11

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015 Version: 2.0

## 11. TOXICOLOGICAL INFORMATION

Mouse IV LD50 1740mg/kg Rat Oral LD50 > 5000mg/kg

Mineral oil, white

Rat Oral LD50 > 5000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

### Irritation / Sensitization: (Study Type, Species, Severity)

**Benzyl Alcohol** 

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Minimal
Skin Irritation Guinea Pig Moderate

Glycerin, USP

Eye Irritation Rabbit Mild

Sodium lauryl sulfate

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild Moderate

Skin Sensitization - GPMT Guinea Pig Negative Skin Sensitization - LLNA Mouse Negative

Conjugated estrogens

Eye Irritation Rabbit Severe

Mineral oil, white

Skin Irritation Rabbit Slight Eye Irritation Rabbit Slight

## Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Conjugated estrogens

Embryo / Fetal Development Rat Subcutaneous7 mg/kg/day LOAEL Embryotoxicity, Fetotoxicity

Sodium lauryl sulfate

Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogen Status: See below

Conjugated estrogens

IARC: Group 1
NTP: Listed

# 12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Page 8 of 11

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015 Version: 2.0

**Toxicity:** 

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

**Benzyl Alcohol** 

Pimephales promelas (Fathead Minnow) EPA LC50 96 Hours 460 mg/L
Daphnia magna (Water Flea) OECD EC50 48 Hours 230 mg/L

Pseudokirchneriella subcapitata (Green Alga) OECD EC50 72 Hours 500 mg/L

Glycerin, USP

Oncorhynchus mykiss (Rainbow Trout) LD50 96 Hours 50 mg/L Daphnia magna (Water Flea) EC50 24 Hours >500 mg/L

Sodium lauryl sulfate

Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 3.6 mg/L

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

**Benzyl Alcohol** 

Daphnia magna (Water Flea) OECD 21 Day(s) EC50 66 mg/L Reproduction

Persistence and Degradability: No data available

**Benzyl Alcohol** 

OECD Activated sludge Ready 92% After 14 Day(s) Ready

**Bio-accumulative Potential:** 

Partition Coefficient: (Method, pH, Endpoint, Value)

Mobility in Soil: No data available

## 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

## 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Page 9 of 11

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015 Version: 2.0

# **15. REGULATORY INFORMATION**

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

## Canada - WHMIS: Classifications

WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

## Cetyl alcohol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	253-149-0

#### White wax

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

## Sodium lauryl sulfate

CERCLA/SARA 313 Emission reporting	Not Listed	
California Proposition 65	Not Listed	
Inventory - United States TSCA - Sect. 8(b)	Present	
Australia (AICS):	Present	
Standard for the Uniform Scheduling	Schedule 6	
for Drugo and Daisens.		

for Drugs and Poisons:

EU EINECS/ELINCS List 205-788-1

## Water, purified

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	
EU EINECS/ELINCS List	231-791-2

## Methyl stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015

Page 10 of 11

Version: 2.0

## 15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
203-990-4

Glyceryl monostearate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Present

250-705-4

**Benzyl Alcohol** 

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Eisted

Not

Mineral oil, white

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Listed

Not Eisted

Not

Glycerin, USP

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Not Listed

Not Listed

Present

Present

REACH - Annex V - Exemptions from the obligations of Register:

Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an

equivalent level of concern

EU EINECS/ELINCS List 200-289-5

Conjugated estrogens

CERCLA/SARA 313 Emission reporting Not Listed

California Proposition 65 carcinogen, initial date 2/27/87; developmental. initial date 4/1/90

EU EINECS/ELINCS List 235-199-5

Cetyl stearate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

100

Not Listed

\_\_\_\_\_

Material Name: Conjugated Estrogens Vaginal Cream (US)

Revision date: 01-Apr-2015

Page 11 of 11

Version: 2.0

## 15. REGULATORY INFORMATION

Fatty acids, C16-18, esters with propylene glycol

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed
292-936-3

## **16. OTHER INFORMATION**

## Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Carcinogenicity-Cat.1A; H350 - May cause cancer

Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled

Carcinogenic: Category 1

Toxic to reproduction: Category 1

Xn - Harmful

R45 - May cause cancer. R60 - May impair fertility.

R61 - May cause harm to the unborn child.

R22 - Harmful if swallowed.

R20/22 - Harmful by inhalation and if swallowed.

**Data Sources:** Publicly available toxicity information. Pfizer proprietary drug development information. Safety

data sheets for individual ingredients.

Reasons for Revision: Updated Section 3 - Composition / Information on Ingredients. Updated Section 1 -

Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 -

Other Information.

Revision date: 01-Apr-2015

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**